MacroGenics, Inc.

How big is MacroGenics, Inc.?

As of Jun 18, MacroGenics, Inc. has a market capitalization of 86.43 million, with net sales of 154.05 million and a net profit of -55.81 million over the last four quarters. Shareholder's funds are 116.06 million, and total assets amount to 270.56 million.

As of Jun 18, MacroGenics, Inc. has a market capitalization of 86.43 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 154.05 million, while the sum of net profit for the same period is -55.81 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 116.06 million, and total assets amount to 270.56 million.

What does MacroGenics, Inc. do?

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibody-based therapies for cancer, autoimmune disorders, and infectious diseases. As of March 2025, it has a market capitalization of $86.43 million, with net sales of $13 million and a net loss of $41 million.

Overview: <BR>MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases, operating in the Pharmaceuticals & Biotechnology industry with a micro-cap market capitalization.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 13 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -41 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 86.43 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.88 <BR>Return on Equity: -70.54% <BR>Price to Book: 1.09<BR><BR>Contact Details: <BR>Address: 9704 Medical Center Dr, ROCKVILLE MD: 20850-3343 <BR>Tel: 1 301 2515172 <BR>Website: https://www.macrogenics.com/

Should I buy, sell or hold MacroGenics, Inc.?

Who are in the management team of MacroGenics, Inc.?

As of March 2022, the management team of MacroGenics, Inc. includes Dr. Scott Koenig as President and CEO, along with several independent directors, including Mr. Paulo Costa as Chairman.

As of March 2022, the management team of MacroGenics, Inc. includes the following individuals:<BR><BR>- Mr. Paulo Costa, who serves as the Independent Chairman of the Board.<BR>- Dr. Scott Koenig, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Karen Ferrante, who is an Independent Director.<BR>- Mr. Kenneth Galbraith, who is also an Independent Director.<BR>- Mr. Edward Hurwitz, another Independent Director.<BR>- Mr. Scott Jackson, who serves as an Independent Director.<BR>- Dr. Jay Siegel, who is an Independent Director as well.<BR><BR>In summary, the management team consists of a mix of executive leadership and independent directors, with Dr. Scott Koenig holding the top executive position.

Is MacroGenics, Inc. overvalued or undervalued?

As of March 7, 2024, MacroGenics, Inc. is considered overvalued and risky due to poor financial metrics and a year-to-date return of -46.77%, significantly underperforming its peers and the S&P 500.

As of 7 March 2024, the valuation grade for MacroGenics, Inc. has moved from attractive to risky, indicating a significant deterioration in its valuation outlook. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 1.42, an EV to EBIT of 0.37, and an EV to EBITDA of 0.40, which suggest that the market is pricing the stock higher than its underlying financial performance justifies. <BR><BR>When compared to peers, MacroGenics shows a notably poor performance with a valuation of -3.0562, while KalVista Pharmaceuticals, Inc. has a similar risky rating at -4.3845, and Coherus BioSciences, Inc. is at -1.0829. This indicates that MacroGenics is not only struggling relative to its peers but also reflects a broader trend of underperformance, as evidenced by its year-to-date return of -46.77% compared to the S&P 500's 12.22%. Overall, the combination of its valuation metrics and poor stock performance suggests that MacroGenics, Inc. is overvalued in the current market environment.

Is MacroGenics, Inc. technically bullish or bearish?

As of August 22, 2025, MacroGenics, Inc. shows a mildly bearish trend with mixed technical indicators, having outperformed the S&P 500 in the short term but significantly underperformed year-to-date.

As of 22 August 2025, the technical trend for MacroGenics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, with key indicators showing mixed signals. The MACD is mildly bullish on both weekly and monthly time frames, while the moving averages indicate a mildly bearish trend on the daily. The Bollinger Bands present a bullish signal weekly but bearish monthly, and the KST is bullish weekly but bearish monthly. The Dow Theory shows a mildly bearish stance weekly and mildly bullish monthly. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 4.85% and 13.82%, respectively, but has significantly underperformed over longer periods, including a year-to-date return of -46.77% compared to the S&P 500's 12.22%.